While anti-VEGF agents (e.g., ranibizumab and aflibercept) can reduce NV growth and vascular leakage-associated eye diseases (e.g., PDR and wet AMD), therapeutic challenges remain, including the need for chronic treatment and a significant number of patients who do not respond11; gene therapy targeting genomic VEGFR2 using AAV-CRIPSR/Cas9 may provide a novel alternative approach. Here, KDR is linked to wet macular degeneration.